FREMONT, CA: Pharmatech Associates, a provider of consulting and services to regulated life science industry, collaborates with InQui Capital, a consulting and investment firm in life science sector, for the ‘Pharmatech connect program’ through which development opportunities will be offered to the early to mid-stage life sciences companies.
This collaboration is aimed at helping the early stage life science technology companies in the areas of investments, market expansion and strategic alliances worldwide. The program services include identification and introduction of investors to cover the full range of development costs encompassing expertise in: global regulatory, technical development, manufacturing and compliance requirements, strategic partnering, business development and global healthcare investment services, reports Business Wire.
“Leveraging our experience along with that of InQui Capital, Pharmatech Connect is intended to bring together resources to boost the development of novel; biological, pharmaceuticals and medical devices. “The healthcare market is global, and we are working locally and globally with companies to develop better drugs and therapies that result in healthier populations,” said Warren Baker, Chief Executive Officer, Pharmatech Associates.